• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fresenius Kabi launches Simplist Glycopyrrolate injection in U.S.

July 25, 2022 By Sean Whooley

Glycopyrrolate Simplist Fresenius Kabi
[Image from Fresenius Kabi]
Fresenius Kabi announced today that its Glycopyrrolate injection in Simplist prefilled syringes has been made available in the U.S.

The Fresenius Kabi Simplist Glycopyrrolate injection, USP, represents the most recent manufacturer-prepared product available in the company’s proprietary, ready-to-administer portfolio of Simplist prefilled syringes, which the company designed to reduce the amount of time nurses spend preparing doses and documenting waste.

Lake Zurich, Illinois-based Fresenius Kabi’s Glycopyrrolate injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for the reversal of neuromusclar blockade, according to a news release.

“Fresenius Kabi is focused on helping reduce clinician burden by expanding our ready-to-administer offerings,” said John Ducker, president and CEO of Fresenius Kabi USA. “We’re pleased that our Simplist prefilled syringe portfolio now includes Glycopyrrolate injection, USP, which will minimize preparation complexity to streamline workflows and help support patient safety in the U.S.”

The company said it continues to invest in expanding its suite of ready-to-administer offerings to assure pharmacists and nurses have a wide range of prefilled, standard strengths, single-patient delivery system options, from bags to syringes, that streamline medication management form the pharmacy to the bedside, thus eliminating the steps in which errors can occur.

Fresenius Kabi’s Simplist Glycopyrrolate injection, USP, is formulated, filled and packaged in the U.S., the company said. Additionally, it is said to represent the company’s commitment to investing “more in America,” as Fresenius Kabi looks to focus efforts on providing more supply, more science, more support and more care to its customers and the patients they serve in the U.S.

To date, the company has invested nearly $1 billion to modernize and expand advanced U.S. pharmaceutical production and distribution facilities.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: freseniuskabi

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS